BeOne Medicines reports first ever profit amid strong revenue growth

BeOne Medicines Ltd. reported total revenues of $2,432.6m for the six months ended June 30, 2025, a 44.7% increase from $1,680.8m in the prior-year period. This growth was primarily driven by a 44.5% surge in product revenue to $2,410.6m, largely attributed to increased sales of BRUKINSA and TEVIMBRA, as well as in-licensed Amgen products. Global sales of BRUKINSA alone reached $1,741.5m, marking a 54.7% increase.

The company achieved a net income of $95.6m for the six months ended June 30, 2025, a substantial improvement from a net loss of $371.6m in the same period of 2024. Basic and diluted earnings per share were $0.07. Total operating expenses increased by 12.2% to $2,004.0m. Research and development expenses rose by 10.0% to $1,006.8m, while selling, general, and administrative expenses increased by 14.5% to $997.2m.

As of June 30, 2025, cash and cash equivalents totaled $2,756.1m, with total assets reaching $6,298.4m. The company's total debt decreased by 6.2% to $954.5m from December 31, 2024. Operating activities provided $307.7m in cash, a significant improvement from the $404.2m used in the prior-year period.